What if you could combine two appetite-suppressing hormones into a single weekly injection — and get even better results than either one alone? That’s exactly what Novo Nordisk has done with CagriSema, a dual-agonist combination that pairs semaglutide (the active ingredient in Wegovy and Ozempic) with cagrilintide, a long-acting amylin analog. Submitted to the FDA in December 2025, CagriSema could become available later in 2026.
Understanding the Science: Why Two Hormones?
You already know about GLP-1 — the gut hormone that reduces appetite and slows gastric emptying. But your body uses multiple hormones to regulate hunger and satiety. Amylin is another one, co-secreted with insulin from the pancreas after meals. It complements GLP-1 by promoting fullness through a different brain pathway, slowing nutrient absorption, and reducing post-meal blood sugar spikes.
By targeting both the GLP-1 and amylin pathways simultaneously, CagriSema creates a more comprehensive appetite-suppression effect than either hormone alone. Think of it as attacking hunger from two different angles at once.
Key finding: CagriSema demonstrated approximately 20% body weight loss at 68 weeks in clinical trials, with treatment completers achieving ~23% loss.
Clinical Trial Results
The numbers are impressive. In clinical trials, CagriSema produced approximately 20% mean body weight reduction at 68 weeks. Among participants who stayed on the medication for the full trial duration, the average loss was approximately 23%. For context, that approaches the efficacy of bariatric surgery without an operating room.
These results position CagriSema ahead of standalone semaglutide (~15% in STEP 1) and competitive with tirzepatide (~20-22.5% in SURMOUNT trials), though head-to-head comparisons between CagriSema and tirzepatide have not yet been completed.
How It Works in Practice
CagriSema comes in a dual-chambered injection pen — one chamber contains semaglutide, the other contains cagrilintide. The two medications cannot be pre-mixed due to stability constraints, so the pen keeps them separate until the moment of injection, when both are delivered simultaneously. It’s still a once-weekly injection, same as standard Wegovy.
Side effects in trials were similar to other GLP-1 medications: nausea, diarrhea, constipation, and vomiting, primarily during dose titration. Our guide to managing GLP-1 digestive side effects applies to CagriSema as well.
When Will It Be Available?
Novo Nordisk submitted CagriSema for FDA review in December 2025. A decision is expected sometime in 2026, though the exact timeline depends on the FDA’s review process. The company is also pursuing separate approval for type 2 diabetes and is researching CagriSema for chronic kidney disease and alcohol-related liver disease.
Where CagriSema Fits in the GLP-1 Landscape
The weight loss medication space in 2026 is crowded — in the best possible way for patients. Oral Wegovy offers a needle-free option, orforglipron adds no-restriction convenience, and CagriSema pushes the efficacy ceiling higher. The full 2026 drug pipeline includes even more options on the horizon.
CagriSema will likely be positioned as a premium option for patients who need maximum weight loss — those with severe obesity, multiple comorbidities, or who haven’t achieved sufficient results with single-agent GLP-1 therapy.
Compare telehealth providers offering GLP-1 weight loss programs — with licensed physicians, lab work coordination, and medication delivery.
Compare Providers →The Bottom Line
CagriSema represents the next evolution in obesity pharmacotherapy — combining two hormonal pathways for greater effect. With ~20-23% weight loss in trials and a once-weekly injection format, it could become the most effective non-surgical weight loss option available. If you’re interested in GLP-1 therapy, the best time to start the conversation with a telehealth provider is now — even starting with current medications puts you ahead for when next-generation options arrive.